Private sector case studies: worked answers for corporate dilemmas

A private-sector case study is a compact moral laboratory: a real-world corporate dilemma, stripped of its press-release gloss, in which you play the decision-maker and must choose a course of action that is both ethically defensible and practically workable. Private-sector case studies test whether you can reason about profit, power and people together, because the GS-4 paper devotes a full case-study section to them, typically carrying 20 or 25 marks, and these answers reward structured thinking far more than memorised definitions. This article works through eight such dilemmas end to end, from CSR funds and insider trading to layoffs, toxic discharge, related-party deals and data privacy, so that the method becomes a habit you can carry into the exam hall.

How to work a case study

The companion framework article gives a seven-move method for case studies, and every case below is built on it, so here it is in one breath: open with a hook and a one-line summary of the real conflict; set your guiding compass, the values and constitutional morality that will steer every later judgment; map the stakeholders and what each stands to gain or lose; surface the ethical issues as a crisp list rather than a retelling; name the dilemma and resolve it by weighing the competing goods instead of dodging them; evaluate each option with an honest merit and demerit; and finally commit to one course of action, justified in the language of the values you invoked at the start.

The eight worked cases below demonstrate this method in corporate settings: watch for the compass, the stakeholder map and the options ledger in each one, and borrow the moves for your own answers.

Answer-writing pointers for corporate-case answers

The detailed playbook's case material keeps returning to the same corporate failure modes: the covered-up flaw, the silenced warning, the short-term ledger. Five habits answer them:

• Rank the duties before weighing the options. In every corporate case, obligations run in a fixed order: the law and public safety first, then the fiduciary duty to those you serve, then the employer's commercial interest; most dilemmas dissolve once the hierarchy is on paper.
• Price the cover-up. Put named costs on both columns: this quarter's revenue against the probable cost of discovery (penalties, lawsuits, lost trust, lost licence); examiners reward the option ledger that refuses to treat concealment as free.
• Record, then refuse. Document the risk and the instruction in writing before declining to comply; a refusal without a record is deniable, and deniability is how corporate wrongdoing survives its own paperwork.
• Escalate in sequence. Internal push first, formal written dissent and compliance review next, the regulator only when internal routes are exhausted and the harm is serious; the ladder shows proportionality, not disloyalty.
• Close with a compliance upgrade. A whistleblower channel, a product-safety protocol, an ethics-committee review: the case is an incident, and the answer should prevent its recurrence.

Worked case studies

Each case follows the same anatomy: the situation, the stakeholders, the ethical issues, the options with their merits and demerits, a recommended course of action, and the values invoked. Read them as model answers, not as scripts to memorise: the examiner rewards the structure and the reasoning, and a different set of facts deserves the same disciplined treatment, not a copied conclusion.

The diverted CSR fund

The situation: You are the CSR head of a listed manufacturing company with factories drawing groundwater from a drought-prone district. The board approved this year's CSR budget of six crore rupees for flood-relief housing and the rebuilding of three village schools that still run in tents after last year's floods. With two months left in the financial year, the promoter-chairman summons you and asks you to divert the unspent four crores to sponsor a high-profile international golf tournament the company is title-sponsoring, booking the spend in the accounts as community sports development. The invoices from the event-management agency are visibly inflated, and the agency is owned by the chairman's nephew. Your annual bonus and your continuation in the role depend entirely on the chairman's goodwill, and he makes it clear that signing the file is a test of your loyalty. The district's children, meanwhile, are studying under tarpaulin sheets as the monsoon approaches.

• You, the CSR head: the decision-maker, torn between career security and professional integrity.
• The promoter-chairman: wants prestige spending routed through CSR; controls your appraisal.
• The event agency and the chairman's nephew: stand to gain inflated payments from a related-party deal.
• The flood-affected community: the intended beneficiaries; children studying in tents.
• Shareholders and the regulator: entitled to honest CSR spending under the Companies Act mandate.
• Employees: watch whether the company's stated values survive contact with the chairman's wishes.

Ethical issues and dilemmas: The first issue is the misuse of a statutory obligation: CSR funds are a legal mandate meant for genuine social good, not a branding slush fund. The second is related-party self-dealing, with inflated invoices flowing to the chairman's nephew, which shades into fraud. The third is falsification of records, since the golf sponsorship would be booked as community development. The fourth is the conflict between your private interest in your bonus and your fiduciary duty to shareholders and beneficiaries. The dilemma is loyalty to a powerful superior versus loyalty to the law, the beneficiaries and your own conscience.

Options before you: Three realistic options present themselves, each with a merit and a demerit.

• Sign the file and sponsor the tournament. Merit: you keep the chairman's favour, protect your bonus, and the brand gets visibility. Demerit: you become party to misappropriation and false accounting, the real beneficiaries lose their schools, and the inflated invoices expose you personally if auditors or regulators investigate.
• Refuse outright and resign in protest. Merit: your conscience stays clean and the protest may draw attention. Demerit: the chairman simply replaces you with someone who will sign, the diversion happens anyway, and you lose your leverage to protect the programme.
• Document the instruction, refuse to sign, and escalate to the audit committee. Merit: you create a paper trail, trigger the company's whistle-blower and related-party safeguards, and keep the approved relief programme alive. Demerit: you risk the chairman's retaliation, so the escalation must be factual, written and routed through proper channels rather than framed as a personal attack.

Recommended course of action: Record the chairman's instruction in writing, decline to book relief money as sports spending, and place the matter before the audit committee with the original board-approved CSR plan attached. Proceed with the school-rebuilding programme as sanctioned. Separately, offer the chairman a legitimate route for the tournament: sponsorship from the marketing budget, where it belongs, with arm's-length vendor selection. This refuses the fraud without refusing the chairman's underlying desire for visibility, and it converts a loyalty test into a governance test the company can pass.

The justification rests on three legs. First, the Companies Act CSR provisions make this spending a statutory trust, not the promoter's personal purse. Second, your fiduciary duty runs to the company and its beneficiaries, not to the chairman's nephew. Third, signing inflated invoices would make you a participant in falsification, a criminal exposure no bonus can price. A loyalty that requires breaking the law is not loyalty but complicity.

Values invoked: fiduciary duty, probity, accountability, stakeholder welfare, courage of conviction, and the rule of law.

The trade before the announcement

The situation: You are a junior research analyst at a mid-sized brokerage. Late one evening, while collecting printouts near the conference room, you overhear two senior bankers discussing an unannounced merger involving a listed client your firm covers: the acquirer will offer a forty per cent premium, and the announcement is two days away. Nobody knows you heard it. Your mother needs an urgent surgery your family cannot afford, and a cousin who trades actively messages you the same night asking for a hot tip. One phone call routed through your cousin's account could fund the surgery several times over, and the trade would be nearly impossible to trace to you. Your firm's compliance manual, which you signed on joining, expressly forbids trading on unpublished price-sensitive information. You have forty-eight hours before the news breaks.

• You, the analyst: holder of unpublished price-sensitive information; family medical emergency.
• Your cousin: willing conduit for the trade; would also break the law.
• The brokerage's clients: entitled to a level playing field and to your firm's honest research.
• The listed company's shareholders: would sell cheap to informed insiders without knowing why the price moves.
• The market regulator: polices insider trading; violations carry imprisonment and market bans.
• Your firm: its licence and reputation rest on its employees' compliance.

Ethical issues and dilemmas: The core issue is insider trading: profiting from information asymmetry that ordinary investors cannot access, which corrodes market integrity. There is also breach of confidentiality, since the information came to you in a professional context, and a conflict between filial love and professional duty. The dilemma is sharpened by genuine need: the money would save your mother, which makes the wrong choice feel like the loving one. But need explains temptation; it does not convert theft into care.

Options before you: Three options, weighed honestly.

• Trade through your cousin's account. Merit: the surgery is funded immediately, and detection seems unlikely. Demerit: it is a criminal offence under securities law, it betrays your signed compliance undertaking, surveillance systems routinely catch exactly such patterns, and one exposed trade ends your career in finance permanently.
• Do nothing and simply wait out the forty-eight hours. Merit: you stay within the law and keep your job. Demerit: passivity leaves the information unreported, and if the leak widens you may later be suspected of being its source; silence protects you but not the firm.
• Report the overheard conversation to the compliance officer and recuse yourself. Merit: you protect the firm, create a record that you did not misuse the information, and allow compliance to tighten information barriers. Demerit: it invites uncomfortable questions and colleague suspicion, and it does nothing for the surgery bill, which must then be solved through legitimate means.

Recommended course of action: Do not trade, do not tip, and do not discuss the information with anyone except the compliance officer, to whom you report the overheard conversation the next morning in writing. Ask to be recused from any coverage of the stock until the announcement. For the surgery, pursue legitimate routes: the firm's employee medical cover, a personal loan, hospital payment plans, or government health schemes. The forty-eight-hour window is a test of exactly the kind the compliance manual was written for.

The justification is both legal and ethical. Securities law treats trading on unpublished price-sensitive information as fraud on the market, and ignorance or indirect routing through a cousin is no defence. Ethically, your fiduciary duty to clients and the investing public outweighs private need, because a market where insiders routinely profit is a market ordinary savers eventually abandon. Reporting also protects you: a documented report is the only proof that you chose the right side of the line.

Values invoked: integrity, fiduciary duty, fairness, rule of law, and professional confidentiality.

The river nobody wanted to see

The situation: You are a freshly graduated engineer, three months into your first job at a reputed chemical plant that pays well and carries prestige in your town. On a night shift you notice tankers discharging a sharp-smelling effluent into a drain that leads to the river, and a senior operator casually confirms this happens most nights to save the cost of running the effluent treatment plant. Downstream, villagers depend on the river for drinking water and irrigation, and the local clinic has recorded a cluster of skin and stomach ailments. When you raise it with colleagues, they advise silence: the last person who mentioned it was dismissed within a month. You are the sole breadwinner for your family, supporting ailing parents and two younger siblings on this salary. Your conscience will not let the matter rest, and you are unsure what a right course even looks like from your junior position.

• You, the junior engineer: the witness; economically vulnerable; morally troubled.
• Plant management: saves treatment costs by illegal discharge; punishes dissent.
• Downstream villagers: drink and irrigate from the river; already showing health effects.
• Senior colleagues: complicit through silence; warn you off for your own good.
• The pollution control board: the statutory regulator, apparently unaware or inactive.
• Your family: depends entirely on your salary continuing.

Ethical issues and dilemmas: The first issue is environmental harm and public health: untreated effluent in a drinking-water source is a slow violence against people who cannot protect themselves. The second is corporate illegality dressed as cost-saving. The third is the classic whistleblowing dilemma: loyalty to the employer and obedience to seniors versus duty to strangers downstream. The fourth is your own vulnerability, which makes courage expensive. The dilemma is not whether the discharge is wrong; it is what a junior, sole-earning employee can rightly be expected to do about it.

Options before you: Four paths, from silence to exposure.

• Stay silent and keep your head down. Merit: your salary and family security are preserved, and you avoid becoming a target. Demerit: the discharge continues, villagers keep falling ill, and silence makes you a passive participant in the wrong; a conscience that is ignored does not go quiet, it goes numb.
• Raise it informally with your seniors again, hoping they act. Merit: it gives the company a chance to correct itself without confrontation. Demerit: you have already seen the culture; an informal word leaves no record and exposes you to retaliation with nothing to show for it.
• Document the discharge and escalate in writing internally, with a deadline. Merit: a written complaint to the plant head and the company's ethics channel creates accountability and gives the firm a fair opportunity to stop the violation. Demerit: in a retaliatory culture this may still cost you your job, so copies must be kept securely and outside the office.
• Go directly to the pollution control board and the press. Merit: external pressure stops the harm fastest. Demerit: bypassing internal channels weakens your legal protection as a whistle-blower and may look like disloyalty rather than last-resort action; it is the right second step, not the first.

Recommended course of action: Gather dated evidence, photographs and the clinic's records if villagers will share them, keeping copies outside the workplace. Write a factual complaint to the plant head and the company's whistle-blower channel, stating the violation and giving a short deadline for the effluent treatment plant to be run. If there is no action, or if you face retaliation, escalate to the State Pollution Control Board with your evidence, and seek support from a legal-aid or environmental organisation. Simultaneously, quietly explore alternative employment so that retaliation, if it comes, does not leave your family destitute.

The justification follows the logic of legitimate whistleblowing: the harm is serious, the facts are within your knowledge, internal remedy is attempted first, and external escalation follows only on failure. Public safety outweighs corporate loyalty, because no employment contract can oblige you to watch poisoning in silence. Your vulnerability deserves mitigation, through evidence, legal protection and a fallback plan, but it does not excuse inaction when the stakes are other people's health.

Values invoked: public safety, environmental stewardship, courage of conviction, accountability, and compassion for the vulnerable.

The retrenchment memo

The situation: You head human resources at a manufacturing plant employing 1,200 people, of whom 400 are contract workers who have served between five and eight years. A new chief executive, hired to impress investors before a funding round, hands you a memo: retrench all 400 contract workers within thirty days, without statutory notice or retrenchment compensation, and show the savings in the next quarterly result. He hints that your own position depends on executing this cleanly. You know the law requires notice and compensation, and you know the township around the plant depends on these wages; many workers have children in the company-supported school. The permanent workforce is watching to see whether the company's talk of being a people-first employer means anything. The CEO wants the numbers; the workers want their livelihoods; the law wants its due.

• You, the HR head: must execute or resist an illegal retrenchment order.
• The chief executive: wants lean quarterly numbers before the funding round.
• The 400 contract workers: long-serving; face sudden loss of livelihood without dues.
• Permanent employees: their trust in the employer is on trial.
• Investors: want efficiency, but also a company without legal time bombs.
• The labour department: enforces notice and compensation requirements.

Ethical issues and dilemmas: The first issue is legality: retrenchment without notice and compensation violates labour law, and an HR head who executes it becomes party to the violation. The second is the dignity of labour: workers who gave eight years cannot be discarded like surplus inventory to polish a spreadsheet. The third is short-termism, sacrificing long-term trust and morale for one quarter's optics. The dilemma pits obedience to a superior against obedience to the law and to the workers whose interests you are professionally bound to steward.

Options before you: Three options, each honest about its cost.

• Execute the memo as ordered. Merit: you keep the CEO's confidence and your job, and the quarterly numbers improve. Demerit: you break the law, 400 families lose their income overnight, the permanent workforce learns that the company's values are decoration, and the inevitable legal claims will cost more than the savings.
• Refuse outright and resign. Merit: your integrity is intact. Demerit: the CEO finds a more compliant HR head, the retrenchment happens anyway, and you abandon the workers at the exact moment your position could have protected them.
• Refuse the illegal order in writing and propose a lawful, humane alternative. Merit: you stay within the law, protect the workers' statutory rights, and preserve the company's reputation with investors who dislike legal risk. Demerit: the CEO will be displeased, the savings arrive slower, and you must be prepared for pressure or transfer; the proposal must therefore be practical, not merely moral.

Recommended course of action: Decline the illegal order in writing, citing the specific legal requirements of notice and compensation. Place before the CEO and the board a phased workforce plan: statutory notice and full retrenchment compensation for those who must go, a voluntary separation scheme with enhanced payouts, a reskilling cell run with the local industrial training institute, and priority rehiring when demand recovers. Frame it in the CEO's own language: lawful retrenchment is cheaper than litigation, and investors reward predictable compliance more than one quarter of engineered leanness. If the CEO insists on the illegal route, escalate to the board and, if necessary, the labour authorities.

The justification is that an illegal order is not an order you may obey; professional duty and the law both outrank the CEO's memo. Beyond legality, the stakeholder view shows the memo to be bad business: destroyed morale, legal liability and a reputation as a hire-and-fire employer will cost the company far more than thirty days of wages. Humane process is not charity; it is risk management with a conscience.

Values invoked: dignity of labour, fairness, rule of law, compassion, and long-term stakeholder value.

The rejected consignment

The situation: You are the quality manager of a food-processing company that exports packaged snacks to Europe. A large consignment, worth nearly two crores, has just been rejected by the European buyer's inspectors: contamination levels exceed the permissible limit, and the buyer has blacklisted the batch. The managing director calls you in and orders the consignment repackaged and cleared for the domestic market, where enforcement is patchy and the brand is trusted by millions of households. Your inspection team, under pressure, has already signed the clearance papers; your signature is the last one needed. You have seen the lab reports yourself: the contamination is real, and it is the kind that harms children and the elderly first. The company cannot easily absorb a two-crore loss in a thin-margin year, and the MD reminds you that everyone else has signed.

• You, the quality manager: the final signature; the only one who has not yet signed.
• The managing director: wants the loss recovered through domestic sales.
• Your inspection team: signed under pressure; watching what you do.
• Domestic consumers: trust the brand; include the most vulnerable age groups.
• The food safety regulator: sets the domestic standard the batch fails.
• The brand itself: its long-term trust is worth more than one consignment.

Ethical issues and dilemmas: The first issue is dual standards: a product deemed unfit for European consumers is somehow deemed fit for Indian ones, which treats domestic lives as cheaper. The second is public health, a non-negotiable duty that no commercial loss can override. The third is honesty: selling a rejected batch under the same trusted label is deception. The dilemma is framed as the company's survival versus consumer safety, but that framing is false, because a food company caught poisoning its customers does not survive either.

Options before you: Three options, and only one of them is actually available to a person of integrity.

• Sign and clear the consignment. Merit: the two-crore loss is recovered, the MD is pleased, and you stay in line with the team. Demerit: you certify as safe a product you know is contaminated, endangering children and the elderly; when, not if, this surfaces, the criminal and reputational consequences will dwarf the consignment's value.
• Refuse to sign but say nothing further. Merit: your hands stay clean. Demerit: the consignment will likely be cleared over your head or after your transfer, and your silent refusal protects your conscience while abandoning the consumers you are employed to protect.
• Refuse in writing, escalate to the board, and alert the regulator if the sale proceeds. Merit: the paper trail fixes responsibility where it belongs, the board gets a chance to stop a catastrophe, and the regulator can seize the batch. Demerit: you will face the MD's fury and possible dismissal, so the documentation must be meticulous and securely stored.

Recommended course of action: Decline to sign, recording the lab findings and the MD's instruction in a dated written note. Escalate immediately to the board's audit committee, recommending that the batch be destroyed or reprocessed to standard, and that the root cause in the production line be fixed before the European buyer's trust is lost entirely. Make clear that if the consignment moves toward domestic shelves, you will inform the food safety authority. Offer the constructive alternative the company actually needs: an insurance-backed quality contingency and a genuine corrective-action plan for the buyer.

The justification is deontological at its core: consumer safety is not a variable to be traded against quarterly margins. Beyond duty, the utilitarian arithmetic also fails the MD's plan, because the expected cost of a poisoning scandal, regulatory action and brand collapse vastly exceeds two crores. A quality manager's signature is a public trust, and lending it to a known hazard is professional misconduct by any code.

Values invoked: public safety, honesty, accountability, professional integrity, and consumer sovereignty.

The contract and the brother-in-law

The situation: You head procurement for a fast-growing logistics company. Bids are invited for a three-year fleet-maintenance contract worth twelve crores, and among the bidders is a firm owned by your brother-in-law. His company is technically competent and his bid is competitive, though not the lowest; it is also no secret in the family that his business is struggling and this contract would rescue it. The management trusts you completely and has left the evaluation to you, which is exactly what worries you: any award to your relative will look like favouritism, however clean the process, and a rival bidder who loses is likely to allege exactly that. Your sister calls to say the family is counting on you. The evaluation criteria were published before bids opened, and your brother-in-law's firm genuinely meets them.

• You, the procurement head: the evaluator; related to one bidder; trusted by management.
• Your brother-in-law: a competent bidder whose firm needs the contract.
• Competing bidders: entitled to a fair, unbiased evaluation.
• The company's management and shareholders: need the best-value vendor, chosen cleanly.
• Your family: exerting emotional pressure for the award.

Ethical issues and dilemmas: The central issue is conflict of interest: your private interest in your family's welfare pulls against your professional duty of impartial evaluation. Closely linked is the appearance of bias, which in procurement matters almost as much as bias itself, because trust in the process is what keeps vendors bidding honestly. There is also the question of whether a competent relative should be punished for the relationship by automatic disqualification. The dilemma is family loyalty versus professional integrity, with management's blind trust making the temptation entirely private.

Options before you: Four options, ranging from favour to fairness.

• Award the contract to your brother-in-law. Merit: the family is rescued, and his firm is genuinely competent. Demerit: it is favouritism in substance or at minimum in appearance; losing bidders will allege bias, management's trust in you is betrayed, and you create a precedent that family ties win contracts.
• Disqualify his firm outright to avoid suspicion. Merit: no one can accuse you of bias. Demerit: it is unfair in the opposite direction, punishing a competent vendor for his marriage, and it may cost the company the best-value bid; overcorrection is still a distortion.
• Disclose the relationship in writing and recuse yourself from the evaluation. Merit: an independent committee scores all bids against the pre-published criteria, so the outcome is defensible whichever way it goes; your integrity is protected by process, not by self-denial. Demerit: gossip may persist regardless, and recusal requires you to genuinely step back, not steer the committee informally.
• Let him withdraw voluntarily after a quiet word. Merit: the conflict disappears without paperwork. Demerit: it pressures a legitimate bidder to surrender his chance, and the quiet word itself is an abuse of your position; it solves your discomfort by sacrificing his right.

Recommended course of action: Disclose the relationship to the management in writing before evaluation begins, recuse yourself completely from scoring and from any discussion of this tender, and have an independent committee evaluate all bids against the pre-published criteria with the scoring sheet retained on file. Accept the outcome, whether your brother-in-law wins or loses, and tell your family plainly that the process, not you, will decide. If the company lacks a formal related-party procurement policy, recommend adopting one after this tender.

The justification is that in fiduciary roles the process must be above suspicion, not merely above actual bias. Recusal plus independent evaluation is the standard remedy for conflicts of interest precisely because it protects all three parties: the company gets a clean award, the bidders get fairness, and you keep both your integrity and your family relationships. Neither awarding nor disqualifying on the basis of kinship is defensible; only the merits, judged by others, are.

Values invoked: impartiality, transparency, integrity, accountability, and fairness.

The plant on the riverbank

The situation: You are the project director of a transnational materials company. The board has approved a new plant in an underdeveloped region: the state offers a five-year tax holiday, the plant uses energy-efficient technology that cuts production cost by a fifth, and the investment aligns with the government's push to industrialise backward areas. But the site sits on a riverbank where fishing families have lived for generations. The plant will draw heavily on the river, raise the cost of living, and bring in thousands of migrant workers, straining a tranquil social order. Protests have begun; the company has responded with a glossy brochure about its CSR policy, which has convinced no one, and some residents are now approaching the judiciary after their petition to the government failed. The board wants your recommendation: push ahead, redesign, or walk away.

• You, the project director: must advise the board; accountable for the project's legitimacy.
• The board and shareholders: want returns, the tax holiday and timely execution.
• Fishing families and residents: face displacement, water stress and cultural disruption.
• The state government: wants investment and jobs; offered the tax holiday.
• The judiciary: now seized of residents' pleas; will test the project's legality.
• Future generations: will inherit the river and the region's ecology.

Ethical issues and dilemmas: The first issue is development versus displacement: whose prosperity counts, and who pays for it. The second is intergenerational equity, since river depletion and ecological damage outlast any tax holiday. The third is consent: a CSR brochure is not consultation, and charity cannot substitute for rights. The fourth is the gap between legal compliance and moral legitimacy; a project can clear paperwork and still be unjust. The dilemma is shareholder returns and regional employment on one side, and the lives and livelihoods of a vulnerable community on the other.

Options before you: Three strategic options for the board.

• Push ahead with the original plan, using legal and police support against protests. Merit: timelines hold, the tax holiday is captured, and shareholders see decisive execution. Demerit: forced displacement invites prolonged litigation, reputational damage and operational sabotage; a plant at war with its neighbours is never truly efficient.
• Abandon the site entirely. Merit: the community is spared, and the company avoids a reputational quagmire. Demerit: the region loses investment and jobs, the tax benefit is wasted, and withdrawal after protests teaches every future project that opposition, however small, vetoes development.
• Pause, assess independently, and negotiate a binding community agreement. Merit: an independent environmental and social impact assessment, negotiated resettlement, guaranteed water shares, local hiring quotas and a grievance mechanism give the project legitimacy that no brochure can buy. Demerit: it costs time and money, delays returns, and requires the board to accept the community as a negotiating partner rather than an obstacle.

Recommended course of action: Recommend the third option: pause construction, commission an independent environmental and social impact assessment with community participation, and negotiate a binding agreement covering fair resettlement, protected water allocation for fishing families, local employment and training quotas, and a permanent grievance redressal mechanism. Make the CSR programme additional to these commitments, not a substitute for them. Proceed only when the agreement is signed and the assessment's conditions are met; if credible consent proves impossible, advise the board to relocate rather than coerce.

The justification draws on stakeholder theory and sustainable development: a project that impoverishes its host community is not development but extraction, and courts increasingly agree. Negotiated consent is also hard-headed business: the cost of delay for proper consultation is a fraction of the cost of a decade of litigation and protest. Development that needs police protection from its beneficiaries has already failed its ethical audit.

Values invoked: justice, sustainable development, intergenerational equity, stakeholder engagement, and respect for community rights.

The data beneath the dashboard

The situation: You are the product manager of a health-tech startup whose app helps patients track chronic conditions. The company's new analytics product sells aggregated insights to advertisers and insurers, and the privacy policy assures users that all data is anonymised. While reviewing the data pipeline, you discover the anonymisation is cosmetic: with a few basic cross-references, individual patients can be re-identified, including their diagnoses and medication histories. The chief executive knows the revenue line depends on this product and the next funding round closes in a quarter; when you raise it, he calls your concern theoretical and asks whether you want the company to survive. Two engineers have quietly told you they share your unease but will not speak up. Thousands of patients, many managing stigmatised conditions, trust the app with their most sensitive information.

• You, the product manager: discovered the re-identification risk; own the product decision.
• The chief executive and investors: need the revenue line for the funding round.
• Patients and users: entrusted sensitive health data under a promise of anonymisation.
• Advertisers and insurers: buy the data; may use it in ways patients never imagined.
• The data protection regulator: enforces purpose limitation and genuine anonymisation.
• The silent engineers: share your concern but fear for their jobs.

Ethical issues and dilemmas: The first issue is informed consent: patients consented to anonymised research use, not to re-identifiable sale of their diagnoses. The second is deception, since the privacy policy promises what the pipeline does not deliver. The third is the special vulnerability of health data, which can affect insurance, employment and dignity. The fourth is the conflict between the company's survival and its users' rights. The dilemma is sharpened by the CEO's framing, survival versus scruples, which quietly assumes the company has a right to survive by means the users never agreed to.

Options before you: Four options, from complicity to confrontation.

• Ship the product as designed and stay quiet. Merit: the funding round proceeds, your job is safe, and the CEO's trust is kept. Demerit: you become complicit in deceiving thousands of patients; when re-identification is demonstrated, as it inevitably will be, the regulatory penalties and loss of user trust will kill the company you were trying to save.
• Resign quietly. Merit: your conscience is clear and your name is off the product. Demerit: the data sale continues unchanged, the patients remain exposed, and your resignation protects you while abandoning the people whose trust you held.
• Demand genuine anonymisation and a fresh consent refresh before any sale. Merit: it fixes the root cause, keeps the product alive on honest terms, and may even become a competitive advantage in a privacy-conscious market. Demerit: real anonymisation reduces the data's commercial value, the CEO may refuse, and the funding timeline slips.
• Document the risk, escalate to the board, and approach the regulator if the sale continues. Merit: the board, which bears legal liability, gets the facts; regulatory escalation stops the harm if internal routes fail. Demerit: this is a career-ending move at this company if the board sides with the CEO, and it must be done with careful legal advice.

Recommended course of action: Refuse to ship the analytics product in its current form. Document the re-identification risk with a technical demonstration, put it to the CEO and the board in writing, and propose the honest alternative: genuine anonymisation to a recognised standard, a clear consent refresh telling users exactly who buys what, and a data-ethics review for every new buyer. If the board authorises the sale of re-identifiable health data anyway, resign and report the practice to the data protection authority, because no product roadmap outweighs a promise made to patients about their bodies.

The justification is that health data is held in a fiduciary relationship: patients cannot verify your pipeline, so they trust your word, and that asymmetry imposes the highest duty of care. Consent obtained for one purpose cannot be stretched to cover another, and a privacy policy that misdescribes the product is not a technicality but a lie. The CEO's survival argument fails the most basic test: a company that must deceive its users to live does not deserve the funding round it is deceiving them to win.

Values invoked: privacy, honesty, autonomy, fiduciary care, and respect for human dignity.

The corporate case types that recur

Four of the recurring case-study types dominate the private-sector paper. A conflict of interest is a situation in which a decision-maker's personal interests could improperly influence their professional judgment: the pharma sponsorship, the related-party contract. Corruption cases test where aggressive business ends and bribery begins. Leadership cases ask what those at the top owe when fraud or failure surfaces on their watch. Innovation cases ask whether a product may be built simply because it can be built. Read each corporate case by asking which of the four it is; the values to invoke follow from the answer.

The incentive chequebook

The situation: You are a senior physician at a reputed private hospital. A pharmaceutical company's representative offers you an all-expenses foreign 'conference', a monthly 'consultancy' retainer, and gifts for your clinic, in return for prescribing the company's brands preferentially. Your colleagues accept such offers as routine, and your own prescriptions currently favour the cheapest effective generics.

• You, your conscience and your professional licence both in play.
• Your patients, who trust that every prescription serves their health, not your income.
• The pharmaceutical company, buying market share through inducements rather than merit.
• Your colleagues, whose acceptance has normalised the practice.
• The hospital, whose reputation rides on the integrity of its doctors.

Ethical issues and dilemmas: The core clash is between personal gain and the fiduciary duty a doctor owes every patient. Inducements skew prescribing toward promoted brands and inflate patients' bills, violating beneficence, the duty to act in the patient's best interest, and non-maleficence, the duty to avoid causing harm. The deals are struck in secret, violating transparency, and they breach the medical profession's own ethical regulations, which prohibit doctors from accepting gifts, travel or cash from pharmaceutical companies. The Uniform Code of Pharmaceutical Marketing Practices (UCPMP) is the industry code that requires drug promotion to be truthful and prohibits inducements to prescribers; its spirit is violated even where its letter is dodged.

Options before you: The offers are generous; the arithmetic of conscience is not.

• Option A: Accept the offers and prescribe the company's brands. Merit: personal gain and easy peer acceptance. Demerit: your prescriptions become sales targets, and patients pay the markup.
• Option B: Decline quietly and continue prescribing on merit. Merit: your integrity and your patients stay intact. Demerit: the system that made the offer keeps making it to others.
• Option C: Decline, document the offers, and raise the practice with the hospital's ethics committee and through the medical council's proper channel. Merit: it attacks the practice, not just your own temptation. Demerit: whistleblowing carries professional risk.

Recommended course of action: Choose C, with B as the minimum any honest doctor must meet. Decline every inducement, keep a written record of the offers, and report the pattern to the hospital ethics committee and the medical council. Continue prescribing the cheapest effective medicine. Note the asymmetry the case exposes: penalties currently fall on doctors while companies face little accountability, so the answer should recommend that marketing codes bind manufacturers with equal force.

Values invoked: Integrity, because a prescription must be a medical judgment, not a sales receipt. Fidelity, because the trust of the sick is not for sale. Justice, because inflated drug costs fall hardest on the poorest patients.

Two more worked cases from the detailed playbook

Two further corporate cases, adapted from the detailed ethics playbook, apply the same seven moves. Watch for the fiduciary hierarchy and the option ledger in each.

The launch with a hidden flaw

The situation: You are the marketing manager of a global technology company. A new flagship product is midway through an aggressive pre-order campaign when you discover a significant flaw: under foreseeable conditions it can compromise user safety, opening the door to data breaches, financial losses and even physical harm. You report it immediately. Your superiors, under intense pressure to meet the launch deadline and sales targets, instruct you to continue the campaign without disclosing the flaw to customers.

• Customers and users: will buy in ignorance what they would not buy informed; their safety and money are at stake.
• You, the marketing manager: the one asked to sell what you know is unsafe.
• Superiors and the product team: measured on the launch; afraid of delay, reputational damage and lost revenue.
• Legal, compliance and regulators: own the question of what the law requires when a company knows of a danger.
• The company's long-term reputation: an asset no quarterly target can buy back once spent.

Ethical issues and dilemmas: The first issue is user safety versus financial interest: the company's short-term ledger against foreseeable harm to strangers. The second is transparency and trust versus the launch calendar. The third is obedience: an instruction from a superior does not convert an unsafe product into an ethical one, and professional responsibility is not discharged by pointing upward.

Options before you: Four responses, from complicity to conscience, each priced honestly.

• Option A: Proceed with the campaign as instructed, saying nothing. Merit: the launch stays on schedule and your position is safe. Demerit: you become complicit in deceiving customers; when the flaw surfaces, as flaws do, the legal liability and the destruction of trust will cost multiples of the delayed launch.
• Option B: Push internally for delaying the launch and disclosing the flaw. Merit: protects users and preserves long-term trust; a company that recalls honestly is punished once, a company caught hiding is punished forever. Demerit: short-term financial loss and real career risk for the person pushing.
• Option C: Consult legal and compliance formally, in writing. Merit: creates an authoritative record of obligations and a paper trail of your objection. Demerit: it may not resolve the ethical core if the company chooses to proceed anyway.
• Option D: If internal routes fail and the danger is serious, report to the external regulator. Merit: protects users when the company will not. Demerit: personal and professional cost; to be used only after the internal ladder is exhausted.

Recommended course of action: Sequence B, then C, then D. Begin with a documented internal push: a written risk note quantifying the foreseeable harm, proposing delay plus disclosure as the responsible course. If overruled, record your dissent in writing and seek formal guidance from legal and compliance. If the company still ships a product it knows to be dangerous and every internal route is exhausted, escalate to the regulator: the duty to foreseeable victims outweighs the duty of loyalty to an employer, and silence at that point is complicity.

The justification is that safety is not a variable in the marketing mix. Consent obtained by concealing a known danger is not consent; a customer who would not buy if told the truth has been defrauded, not persuaded. And the commercial arithmetic favours honesty too: the short-term gain of a quiet launch is dwarfed by the certain long-term cost of a discovered cover-up.

Values invoked: public safety, honesty, fiduciary care toward customers, and moral courage: the willingness to be the inconvenient person in the room before the launch.

The bug in the payment pipe

The situation: You lead the engineering team of a software company whose payment processing system is used by thousands of businesses. A security review finds a significant flaw: if exploited, it could divert or expose users' money. A proper fix requires taking the system offline for an extended period, disrupting clients and costing the company substantial revenue. Leadership wants the flaw handled quietly, without downtime.

• Users: whose money moves through the pipe; they cannot see the flaw and cannot protect themselves.
• Client businesses: depend on the system for their own revenue; downtime hurts them too.
• You and the engineering team: know the risk precisely and will own the outcome.
• Company leadership: weighing revenue and reputation against an invisible danger.

Ethical issues and dilemmas: The central issue is the security of other people's money versus service continuity and revenue. Beneath it lies transparency: users and clients have a right to know when the system holding their funds is at risk, and silent patching treats their ignorance as the company's convenience.

Options before you: Four technical paths, each with an ethical price tag.

• Option A: Shut the system down immediately and fix. Merit: maximum protection for users' money. Demerit: unplanned disruption; clients lose revenue without warning; a rushed fix risks new errors.
• Option B: Announced, scheduled maintenance in off-peak hours. Merit: transparency builds trust; clients can prepare; the fix is done properly under controlled conditions. Demerit: a brief, known exposure window and the honest cost of downtime.
• Option C: Patch silently in stages without downtime. Merit: no disruption. Demerit: partial fixes leave windows of exposure, and the dishonesty compounds: users are kept in the dark about a risk to their own money.
• Option D: A temporary workaround with monitoring, full fix later. Merit: continuity preserved. Demerit: users stay at risk longer, betting their money on the hope that no attacker finds the flaw first.

Recommended course of action: Choose B. Scheduled, announced maintenance is the honest middle that refuses both panic and concealment: it fixes the flaw properly while respecting clients through advance notice and off-peak timing. Announce the window, explain in plain language that a security improvement requires downtime, fix and verify, and publish a post-incident note. The short-term cost of honesty is the premium on the trust the business runs on.

The justification is fiduciary: the company holds other people's money in its system, and that asymmetry imposes the highest duty of care. A flaw that can lose users' funds is not an internal engineering matter but a breach of that duty until fixed, and users cannot consent to a risk they are not told about.

Values invoked: transparency, fiduciary care, honesty, and risk management: addressing the flaw in a controlled manner before it is widely known or exploited.

Key Terms

• Fiduciary duty: Fiduciary duty is the obligation of a person in a position of trust, such as a director, manager or fund steward, to act solely in the best interests of those they serve, with loyalty, care and obedience to the mandate; it is the backbone of most private-sector case answers.
• Stakeholder theory: Stakeholder theory is the view, associated with R. Edward Freeman, that a company owes duties not only to shareholders but to all groups affected by its actions, including workers, customers, communities and the environment; it is the usual counterweight to shareholder primacy in GS-4 answers.
• Whistleblowing: Whistleblowing is the disclosure, by a member of an organisation, of illegal or unethical conduct within it, first through internal channels and then, if those fail, to regulators or the public; legitimate whistleblowing requires serious harm, verified facts and internal remedy attempted first.
• Conflict of interest: A conflict of interest is a situation in which a person's private interests, such as family ties or financial gain, pull against their professional duty to decide impartially; the standard remedies are disclosure, recusal and independent evaluation.
• Insider trading: Insider trading is buying or selling securities on the basis of unpublished price-sensitive information, which defrauds the market by exploiting an asymmetry ordinary investors cannot overcome; it is a criminal offence under securities law.
• Related-party transaction: A related-party transaction is a business deal between a company and its own promoters, directors or their relatives; such deals are legal only when conducted at arm's length, with full disclosure and independent approval.
• Corporate Social Responsibility: Corporate Social Responsibility is a company's obligation to contribute to social good beyond profit-making, given statutory form in India by the Companies Act provisions mandating qualifying companies to spend on prescribed social activities; the funds are a legal trust, not a branding budget.
• Probity: Probity is complete and confirmed integrity in the handling of money and power, especially funds held in trust; in case studies it is the value most directly violated by diversion, inflated invoices and false accounting.
• Informed consent: Informed consent is agreement given with full understanding of what is being agreed to, including purposes, risks and beneficiaries; consent for one use of data or resources cannot be stretched silently to cover another.
• Environmental stewardship: Environmental stewardship is the duty to manage natural resources so that present use does not destroy the prospects of future generations; it underpins the answers on effluent discharge, plant siting and intergenerational equity.
• Due diligence: Due diligence is the careful, documented verification of facts before a decision, such as checking lab reports, bid criteria or anonymisation claims; its absence is what turns most of these cases from dilemmas into disasters.
• Moral courage: Moral courage is the willingness to act on one's ethical judgment despite personal cost, such as career risk or retaliation; case-study answers invoke it wherever the right course is also the frightening one.
• Duty of care: the obligation to take reasonable care to avoid foreseeable harm to others; in corporate settings, the reason a company may not trade user safety for revenue or a quiet quarter.

Practice questions

Five original drills in PYQ style. Work each one with the full method: hook and summary, compass, stakeholders, issues, options with merits and demerits, and a committed course of action.

You are the chief financial officer of a listed company preparing a rights issue. The promoter asks you to recognise next quarter's expected sales in this quarter's books and to capitalise routine expenses, so that the issue price looks stronger. The statutory auditor, a long-time family friend of the promoter, signals he will not object. Your finance team is uneasy but silent, and the issue's success will fund a genuine expansion that creates two thousand jobs.

• Question 1: Identify the ethical and legal issues in window-dressing the accounts ahead of a rights issue.
• Question 2: Evaluate your options and lay out the course of action you would adopt, with reasons.

Framing hint: an earnings-management archetype testing the line between creative accounting and fraud; auditor independence is compromised by the family friendship, so the audit committee and the regulator are your real audience.

You lead the data-science team of a recruitment-tech firm. Your flagship hiring algorithm, already deployed at three large clients, is found to systematically rank women lower for technical roles because it was trained on a decade of male-dominated hiring data. The chief executive wants it shipped to a fourth client next week as is, arguing that fixing the bias will take a quarter and the contract will be lost. The affected candidates will never know why they were rejected.

• Question 1: What are the ethical issues in deploying a hiring algorithm known to discriminate?
• Question 2: What course of action would you recommend to the management, and how would you justify the commercial cost of delay?

Framing hint: an algorithmic-fairness archetype; disparate impact without intent is still discrimination, and opacity toward candidates removes their only defence, so the fix must precede the sale.

You are the HR head of a factory where wage negotiations begin next month. Two senior managers demand that you transfer the elected union leader to a remote depot before talks start, calling it a routine administrative move. The transfer rules technically permit it, the union will read it as intimidation, and the last time this happened the factory lost forty production days to a strike. The managers hint your promotion file is under review.

• Question 1: Analyse the ethical issues in using a technically legal transfer to weaken collective bargaining.
• Question 2: What would you do, and what systemic safeguards would you propose for future negotiations?

Framing hint: a freedom-of-association archetype testing whether technical legality excuses an unfair labour practice; short-term bargaining advantage bought this way reliably costs more in strikes and trust.

You are the compliance officer of a pharmaceutical distributor. Your star deal-maker, who brings in a third of the company's revenue, routes lavish gifts, foreign trips and school admissions for the procurement officers of client hospitals through entertainment expenses. He calls it relationship-building in a competitive market; you recognise the pattern as bribery with receipts. The managing director asks you to handle it quietly so the revenue is not disturbed.

• Question 1: Where does legitimate relationship-building end and bribery begin in this case? Identify the issues.
• Question 2: Evaluate your options, from quiet handling to formal action, and choose your course with reasons.

Framing hint: a gifts-versus-bribes boundary archetype; tone at the top is being set by the request for quiet handling, so the answer must address the system, not just the star performer.

You are an independent director on the board of a cement company. Management proposes buying cheap carbon offsets of dubious quality, with weak verification of whether any emissions were actually avoided, so the company can declare itself net zero before a global investor summit. Real emission cuts would cost ten times more and take three years. The sustainability report is already drafted with the net-zero claim on its cover.

• Question 1: What are the ethical issues in claiming net zero through offsets of uncertain integrity?
• Question 2: What course of action would you advise the board, balancing investor expectations with honesty?

Framing hint: a greenwashing archetype testing additionality and substance over disclosure; a net-zero claim is a public promise, and a promise built on paper credits is a misrepresentation whatever the auditors sign.

You are the compliance head of a mid-sized pharmaceutical company. An internal audit reveals that the marketing team has been funnelling 'speaker fees' to doctors who prescribe the company's cardiac drugs at high volumes. The CEO asks you to handle it quietly: stop the payments going forward, but bury the audit to protect the share price.

• Question 1: Identify the ethical issues, including the conflict of interest imposed on the doctors and the asymmetry of accountability between companies and prescribers.
• Question 2: What course of action do you recommend to the board, and what systemic controls would you put in place to prevent recurrence?

Framing hint: a burial protects the share price and poisons the company; compliance that cannot say no to the CEO is decoration, not governance.